Exclusive: US FDA taps Merck drugs with blockbuster sales potential for national priority vouchers

Core Insights - The U.S. Food and Drug Administration (FDA) is expediting the review process for two experimental drugs developed by Merck, which have the potential to generate multibillion-dollar revenues [1] Company Summary - Merck is currently in the spotlight due to the FDA's decision to fast-track the review of its two experimental drugs, indicating a significant opportunity for the company in the pharmaceutical market [1]